Eastern Cooperative Oncology Group

东部肿瘤合作组

• 批准号: 6935212
• 负责人: thomas matthew habermann
• 金额: $ 22.02万
• 依托单位: MAYO CLINIC ROCHESTER
• 依托单位国家: 美国
• 财政年份: 1978
• 资助国家: 美国
• 起止时间: 1978-06-01 至 2010-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6935212
• 关键词: antineoplastics; bone marrow transplantation; brain neoplasms; breast neoplasms; cancer prevention; clinical research; clinical trials; combination cancer therapy; combination chemotherapy; cooperative study; fluorescent in situ hybridization; gastrointestinal neoplasms; gene therapy; head /neck neoplasm; health behavior; human subject; human therapy evaluation; leukemia; lymphoma; melanoma; multiple myeloma; neoplasm /cancer chemotherapy; neoplasm /cancer genetics; neoplasm /cancer immunotherapy; neoplasm /cancer pharmacology; neoplasm /cancer radiation therapy; neoplasm /cancer surgery; neoplasm /cancer vaccine; nucleic acid sequence; oncology; pathology; prognosis; reproductive system neoplasm; thorax neoplasm; tissue resource /registry; urinary tract neoplasms

DESCRIPTION (provided by applicant): The Mayo Clinic has been a member of the Eastern Cooperative Oncology Group for 30 years. The purpose of this grant application is to support the continued membership of the Mayo Clinic in the Eastern Cooperative Oncology Group. The goals are directed toward a greater understanding of malignancies, a better understanding of related problems in malignant diseases, development of improved treatment programs in malignant diseases, and improved patient survival in malignant diseases. Mayo Clinic has the resources, personnel, facilities, and patient population to facilitate strong contributions to the research programs of ECOG. With the continued growth and development of the Mayo medical practice, we would anticipate significant protocol entry and scientific contributions. The ECOG affiliation with its strong treatment and ancillary laboratory programs which have evolved provide major benefits to Mayo Clinic, its investigators, its affiliated regional cancer programs, and the large group of patients with malignant diseases who are involved in these research activities. The specific aims of this grant proposal are to support the following aspects of Mayo Clinic ECOG research activities which include the following: 1.) evaluation of new protocol design and treatment regimens to provide group-wide ECOG Phase II and Phase III treatment protocols in malignant diseases; 2.) coordination of, and participation in, adjunctive laboratory-based correlative studies in association with ECOG treatment protocols in malignant diseases; 3.) development of new prognostic factors and indexes in hematologic malignancies; 4.) participation in disease-specific accrual and activities; 5.) and participation in administrative activities in ECOG. These aims will be incorporated into a clinical trial infrastructure that is focused on institutional patient quality of care, clinical research associate (CRA) development, and faculty development.

描述（由申请人提供）：马约诊所30年来一直是东部肿瘤协作组的成员。 本拨款申请的目的是支持马约诊所继续成为东部肿瘤协作组的成员。 这些目标旨在更好地了解恶性肿瘤，更好地了解恶性疾病中的相关问题，制定改进的恶性疾病治疗方案，并提高恶性疾病患者的生存率。 马约诊所拥有资源、人员、设施和患者人群，可为ECOG研究项目做出重大贡献。 随着马约医疗实践的持续增长和发展，我们预计会有重大的方案进入和科学贡献。 ECOG与其强大的治疗和辅助实验室项目的联系已经发展，为马约诊所、其研究者、其附属的区域癌症项目以及参与这些研究活动的大量恶性疾病患者提供了重大益处。 该资助提案的具体目的是支持马约诊所ECOG研究活动的以下方面，包括：1.）评估新的方案设计和治疗方案，以提供恶性疾病的全组ECOG II期和III期治疗方案; 2.）协调并参与与恶性疾病ECOG治疗方案相关的连续性实验室相关研究; 3.）发展新的血液恶性肿瘤预后因子和指标; 4.） 参与特定疾病的应计费用和活动; 5.）并参与西非经共体的行政活动。 这些目标将被纳入临床试验基础设施，重点是机构患者护理质量，临床研究助理（CRA）的发展和教师的发展。